Statins stimulate arachidonic acid release and prostaglandin I(2 )production in rat liver cells by Levine, Lawrence
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Lipids in Health and Disease
Open Access Research
Statins stimulate arachidonic acid release and prostaglandin I2 
production in rat liver cells
Lawrence Levine*
Address: Department of Biochemistry, Brandeis University Waltham, MA 02454, USA
Email: Lawrence Levine* - llevine@brandeis.edu
* Corresponding author    
Abstract
Statins inhibit 3-hydroxy-3-methylglutaryl (HMG-CoA) reductase, the rate limiting step in
cholesterol synthesis. They are, therefore, used clinically to lower cholesterol and prevent
atherosclerosis. Statins have beneficial effects on multiple organ systems. Some of these effects are
found in the absence of significant changes in cholesterol levels. Polyunsaturated fatty acids also
inhibit HMG-CoA reductase and have many of the same beneficial effects of statins. Four statins
(mevastatin, lovastatin, simvastatin and atorvastatin) have been tested in rat liver cells for their
effect on arachidonic acid (AA) release and prostaglandin I2 production induced in the presence of
lactacystin and 12-O-tetradecanoylphorbol-13-acetate. Each statin stimulated release of AA and
induced prostaglandin I2 production. Mevalonate, the product of HMG-CoA reductase, did not
reduce the stimulation observed in the presence of simvastatin indicating that HMG-CoA reductase
activity is not involved. In view of the multiple biologic properties of AA, the AA released as a result
of the action of the statins may play a role in some of the pharmacological effects attributed to these
drugs.
Background
The statins, by inhibiting HMG-CoA reductase activity, re-
duce cholesterol and isoprenoid synthesis [1]. They are
being used primarily in the prevention of atherosclerosis
[2,3]. They have proven to be beneficial in preventing
stroke [4] and may increase bone formation [5] and lower
the risk of dementia [6]. Some of the benefits in patients
with myocardial infarction are independent of cholesterol
levels. Statins also inhibit cellular proliferation and in-
duce apoptosis of tumor cells [7]. Essential fatty acids
have several properties similar to the statins [8,9] and Das
[10] has suggested that "essential fatty acids and their me-
tabolites may serve as second messengers of the actions of
statins."
Statins affect prostaglandin (PG) production. Mevastatin
or lovastatin, at 25 µM, induce PGI2 production and cy-
clooxygenase (COX)-2 in human aorta smooth muscle
cells [11]. Mevalonate and geranylgeranyl-pyrophosphate
block these stimulations implicating the cholesterol bio-
synthetic pathway in this up-regulation. However, fluvas-
tatin down-regulates rather than up-regulates COX-2
expression in human umbilical vein endothelial cells [12]
and lovastatin reduces PGI2  production in bovine en-
dothelial cells, human skin fibroblasts and arterial
smooth muscle cells [13].
I observed that in rat liver cells, the statins stimulate the
release of an essential fatty acid, arachidonic acid (AA)
and stimulate production of its metabolite, PGI2. These
stimulations are independent of HMG-CoA reductase ac-
tivity as measured by the lack of any suppression by
mevalonate.
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Results
The release of AA from rat liver cells after 6 h incubation
with mevastatin, lovastatin and simvastatin is shown in
Fig. 1. An extract of the pharmaceutical product Lipitor®
also significantly stimulates AA release (data not shown).
The release of AA as a function of time in the presence of
50 µM lovastatin or simvastatin is shown in Fig. 2. Stimu-
lation by lovastatin and simvastatin is observed after as lit-
tle as 15 min incubation with cells (the time of release
with mevastatin was not studied). Preincubation of the
cells for 2 h with 1 µM actinomycin did not alter the quan-
tity of AA release stimulated by 6 h incubation with simv-
astatin [17.0 ± 0.30 % (5) was released in the absence of
actinomycin compared to 17.6 ± 0.60 % (5) released in its
presence]. These results indicate that transcription is not
required. I have shown previously that under these condi-
tions, induced PG production is inhibited [14,15]. Nor
does mevalonate, the direct product of HMG-CoA reduct-
ase, affect the stimulated release by 50 µM simvastatin
(Fig. 3).
PGI2 production is enhanced in cells incubated with lac-
tacystin in the presence of TPA (Fig. 4). Simvastatin, mev-
astatin and lovastatin enhance the induced PGI2 levels
(Fig. 4). Even at 70 min the quantity of PGI2 produced by
lactacystin plus TPA increased in the presence of 30 µM
simvastatin (Fig. 5). The effect of 96 µM mevalonate on
simvastatin's amplification of induced PGI2 in the pres-
ence of lactacystin plus TPA is shown in Fig. 6. Mevalonate
does not suppress the stimulated PGI2 production. Meval-
Figure 1
AA release by mevastatin, lovastatin and simvastatin. Cells were incubated with these statins at the concentrations shown for 6 
h. The analyses were performed on triplicate culture dishes. * Statistically significant vs MEM/BSA control (P < 0.05). Data are 
representative of several independent experiments.Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/1
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onate amplifies even further the effect of simvastatin on
lactacystin plus TPA induced PGI2 production, suggesting
a role for a downstream isoprenoid in the induction path-
way (Fig. 6).
Discussion
Mevastatin, lovastatin, simvastatin and atorvastatin stim-
ulate the release of AA from rat liver cells. They do so even
after preincubation with actinomycin. Mevalonate, the
product of HMG-CoA reductase, does not suppress simv-
astatin's stimulated AA release. Therefore, it appears that
neither transcription nor cholesterol biosynthesis is re-
quired for this stimulated AA release. HMG-CoA reductase
activity also is not required for up-regulation of induced
PGI2 production by simvastatin.
AA has a number of important bioactivities. It serves as
substrate for cyclooxygenases, lipoxygenases and cyto-
chrome P450 epoxygenases. After additional enzyme reac-
tions the products yield a variety of biologically active
prostanoids [16]. AA also activates leukocyte NADPH ox-
idase [17], activates PPAR receptors [18], affects H+ chan-
nel [19], K+ channel [20] and Ca 2+ channel activities [21].
It elevates heat shock gene expression [22], induces apop-
tosis [23] and inhibits Ca 2+ induced Ca 2+ release [24]. In
human embryonic kidney cells it down-regulates sterol
regulatory element-binding proteins (SREBPs), especially
the SREBP-1a isoform [25]. The release of AA after incuba-
tion with sulindac and the stimulation of apoptosis via
conversion of sphingomyelin to ceramide [26] is a mech-
anism proposed to mediate cancer chemoprevention by
nonsteroidal anti-inflammatory drugs [26]. I have postu-
lated that, in addition to nonsteroidal anti-inflammatory
drugs, the continuous use of other commonly prescribed
drugs that release AA is potentially cancer preventative
[27].
The major product of PGH2 metabolism by these rat liver
cells is PGI2, although 10% or less of the metabolites are
PGE2 and PGF2α [28]. In this study, only PGI2 was meas-
ured. Although PGI2 synthase is an induced enzyme [29],
the increased PGI2 production probably reflects COX ac-
Figure 2
Time course of release of AA after incubation with 50 µM lovastatin (❍ ), 50 µM simvastatin () and the MEM/BSA controls 
(). Analyses were performed on triplicate or duplicate dishes. The average value is recorded.Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/1
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Figure 3
Effect of 188 µM mevalonate on AA release from rat liver cells incubated 6 h in the presence of 50 µM simvastatin. The analy-
ses were performed on triplicate dishes. The bars show the mean values and brackets the SEM. This experiment was repeated 
two times with similar results.Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/1
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Figure 4
Effect of 27 µM simvastatin, 100 µM mevastatin and 50 µM lovastatin on lactacystin plus TPA induced 6-keto-PGF1α production 
after 6 h incubation. At the levels tested, simvastatin, mevastatin and lovastatin alone do significantly stimulate basal PGI2 pro-
duction, but by < 1 ng/ml. The analyses were performed on triplicate dishes. * Statistically significant vs lactacystin plus TPA (P 
< 0.05). This experiment was repeated with similar results.Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/1
Page 6 of 9
(page number not for citation purposes)
tivity [27]. Up-regulation of PGI2  production is in
agreement with the findings of Degreave et al [11] who
showed that mevastatin and lovastatin up-regulate COX
activity in human aortic smooth muscle cells. However,
while up-regulation in the muscle cell system involves
cholesterol biosynthesis, the up-regulation observed in rat
liver cells does not. Statins also have been shown to
down-regulate COX activity in human umbilical vein en-
dothelial cells [12]. In addition to differences inherent in
the type of cells being studied by the various investigators,
the apparently contradictory findings may also be due to
examination of the cells at different stages of growth. The
published studies [11–13] use cells at confluent densities
and also may have been in the G0 stage of growth. The rat
liver cells studied in this report were at low density (divid-
ing cells).
Since statins activate at µM concentrations, it is likely that
the release of AA and effects on PGI2 production are reflec-
tions of interaction with cell membranes.
Conclusions
Statins stimulate AA release from and PGI2 production in
rat liver cells. It is not yet possible to assign a biological
consequence to either stimulation. However, in view of
the many biological activities of AA, its release could
generate the essential fatty acid that is postulated to be a
mediator of statin action [10]. Such mediation does not
involve cholesterol biosynthesis.
Materials
The C-9 rat liver cell line was purchased from the Ameri-
can Type Culture Collection (Manassa, VA, USA). The
Figure 5
Time course of 6-keto-PGF1α production during incubation with MEM/BSA (), 30 µM simvastatin (), lactacystin plus TPA 
(❍ ) and lactacystin plus TPA plus 30 µM simvastatin (*). Analyses were performed on triplicate or duplicate dishes. The aver-
age value is recorded.Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/1
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Figure 6
Effect of 96 µM mevalonate on 6-keto-PGF1α produced by stimulation with 30 µM simvastatin in the presence of lactacystin 
plus TPA after a 6 h incubation. Analyses were performed on triplicate dishes. * Statistically significant vs lactacystin plus TPA (P 
< 0.05) ** Statistically significant vs lactacystin plus TPA and simvastatin (P < 0.05).Lipids in Health and Disease 2003, 2 http://www.Lipidworld.com/content/2/1/1
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cells were maintained in Eagle's minimum essential
medium (MEM) supplemented with 10% fetal bovine se-
rum. The [3H] AA (91.8 Ci/mmol) was from NEN Life Sci-
ence Products, Inc., (Boston, MA, USA). Mevastatin,
lovastatin, DL-mevalonic acid lactone were from Sigma
Chemical Co. (St. Louis, MO, USA). I thank Dr. Gregory
R. Mundy, Institute for Drug Development, San Antonio,
TX, for the generous supply of simvastatin. For the exper-
iments with atorvastatin, CH3CH2OH and CH3OH ex-
tracts of Lipitor® tablets were used.
Methods
On the day prior to experiments, the rat liver cells were
treated with 0.25% trypsin-EDTA and, after addition of
minimal essential media (MEM) containing 10% fetal calf
serum, the floating cells were seeded onto 35 mm culture
dishes. The plating densities varied from 0.1 to 0.5 × 105
cells/35 mm dish. The freshly seeded cultures were incu-
bated 24 h to allow for cell attachment. After decantation
of MEM containing the fetal bovine serum, 1.0 ml fresh
MEM containing 10% fetal bovine serum and [3H] AA
(0.2 µCi/ml) was added and the cells incubated for anoth-
er 24 h. The cells were washed 4 times with MEM and in-
cubated for various periods of time with 1.0 ml of
different concentrations of each compound in MEM
containing 1.0 mg BSA/ml. The culture fluids were then
decanted, centrifuged at 2000 × g for 10 min, and 200 µl
of the supernate counted for radioactivity. Radioactivity
recovered in the washes before the 6 h incubation was
compared to input radioactivity to calculate the % radio-
activity incorporated into the cells [30].
For PGI2 production, 1.0 ml of MEM supplemented with
10% fetal bovine serum, void of [3H] AA, was added after
the first 24 h incubation. The cells were incubated for an-
other 24 h, washed three times with MEM, then incubated
with lactacystin plus TPA and the compounds in MEM
containing BSA for various periods of time. The culture
fluids were decanted and analyzed for 6-keto-PGF1α, the
stable hydrolytic product of PGI2, by radioimmunoassay
[31].
Presentation of data
The [3H] AA release is presented as a percentage of the ra-
dioactivity incorporated by the cells. Three to six culture
dishes were used for each experimental point. The data are
expressed as mean values ± SEM (number of dishes). The
data were statistically evaluated by unpaired Student's t-
test. A P value < 0.05 was considered significant.
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